General discussion, page-11865

it's also relevant to consider the likelihood of us even going forth with a Phase 3 trail.

There's a higher probability for any of IHL's drugs to be bought out after completion of the Phase 2 trials which will rule out Phase 3 altogether, therefore eliminating any calls for (enormous) CR's for Phase 3 trials and also eliminating the chance of any failure to be attached to our company (IHL) record.

As you'll see from the attachment, buyouts have a higher chance of occurring during the season of preclinical studies, or during the season of Phase 2 trials.

Yes, the data is a few years old, however I don't see how the approach of a buyout would differ from what's presented in the attachment.